Literature DB >> 21263067

Host APCs augment in vivo expansion of donor natural regulatory T cells via B7H1/B7.1 in allogeneic recipients.

Tangsheng Yi1, Xiaofan Li, Sheng Yao, Lin Wang, Yuhong Chen, Dongchang Zhao, Heather F Johnston, James S Young, Hongjun Liu, Ivan Todorov, Stephen J Forman, Lieping Chen, Defu Zeng.   

Abstract

Foxp3(+) regulatory T (Treg) cells include thymic-derived natural Treg and conventional T-derived adaptive Treg cells. Both are proposed to play important roles in downregulating inflammatory immune responses. However, the mechanisms of Treg expansion in inflammatory environments remain unclear. In this study, we report that, in an autoimmune-like graft-versus-host disease model of DBA/2 (H-2(d)) donor to BALB/c (H-2(d)) recipients, donor Treg cells in the recipients predominantly originated from expansion of natural Treg cells and few originated from adaptive Treg cells. In vivo neutralization of IFN-γ resulted in a marked reduction of donor natural Treg expansion and exacerbation of graft-versus-host disease, which was associated with downregulation of host APC expression of B7H1. Furthermore, host APC expression of B7H1 was shown to augment donor Treg survival and expansion. Finally, donor Treg interactions with host APCs via B7.1/B7H1 but not PD-1/B7H1 were demonstrated to be critical in augmenting donor Treg survival and expansion. These studies have revealed a new immune regulation loop consisting of T cell-derived IFN-γ, B7H1 expression by APCs, and B7.1 expression by Treg cells.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21263067      PMCID: PMC3786569          DOI: 10.4049/jimmunol.1002939

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  51 in total

1.  B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion.

Authors:  H Dong; G Zhu; K Tamada; L Chen
Journal:  Nat Med       Date:  1999-12       Impact factor: 53.440

Review 2.  Natural versus adaptive regulatory T cells.

Authors:  Jeffrey A Bluestone; Abul K Abbas
Journal:  Nat Rev Immunol       Date:  2003-03       Impact factor: 53.106

3.  Acute graft-versus-host disease does not require alloantigen expression on host epithelium.

Authors:  Takanori Teshima; Rainer Ordemann; Pavan Reddy; Svetlana Gagin; Chen Liu; Kenneth R Cooke; James L M Ferrara
Journal:  Nat Med       Date:  2002-06       Impact factor: 53.440

4.  Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gamma-dependent mechanism.

Authors:  Bruce R Blazar; Beatriz M Carreno; Angela Panoskaltsis-Mortari; Laura Carter; Yoshiko Iwai; Hideo Yagita; Hiroyuki Nishimura; Patricia A Taylor
Journal:  J Immunol       Date:  2003-08-01       Impact factor: 5.422

5.  CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.

Authors:  Matthias Edinger; Petra Hoffmann; Joerg Ermann; Kathryn Drago; C Garrison Fathman; Samuel Strober; Robert S Negrin
Journal:  Nat Med       Date:  2003-08-17       Impact factor: 53.440

6.  Intrathecal delivery of IFN-gamma protects C57BL/6 mice from chronic-progressive experimental autoimmune encephalomyelitis by increasing apoptosis of central nervous system-infiltrating lymphocytes.

Authors:  R Furlan; E Brambilla; F Ruffini; P L Poliani; A Bergami; P C Marconi; D M Franciotta; G Penna; G Comi; L Adorini; G Martino
Journal:  J Immunol       Date:  2001-08-01       Impact factor: 5.422

7.  CD4(+)CD25(+) immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade.

Authors:  P A Taylor; R J Noelle; B R Blazar
Journal:  J Exp Med       Date:  2001-06-04       Impact factor: 14.307

8.  Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3.

Authors:  WanJun Chen; Wenwen Jin; Neil Hardegen; Ke-Jian Lei; Li Li; Nancy Marinos; George McGrady; Sharon M Wahl
Journal:  J Exp Med       Date:  2003-12-15       Impact factor: 14.307

9.  Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation.

Authors:  Petra Hoffmann; Joerg Ermann; Matthias Edinger; C Garrison Fathman; Samuel Strober
Journal:  J Exp Med       Date:  2002-08-05       Impact factor: 14.307

10.  Impaired development of CD4+ CD25+ regulatory T cells in the absence of STAT1: increased susceptibility to autoimmune disease.

Authors:  Takeaki Nishibori; Yoshinari Tanabe; Leon Su; Michael David
Journal:  J Exp Med       Date:  2003-12-29       Impact factor: 14.307

View more
  25 in total

1.  Donor B cells in transplants augment clonal expansion and survival of pathogenic CD4+ T cells that mediate autoimmune-like chronic graft-versus-host disease.

Authors:  James S Young; Tao Wu; Yuhong Chen; Dongchang Zhao; Hongjun Liu; Tangsheng Yi; Heather Johnston; Jeremy Racine; Xiaofan Li; Audrey Wang; Ivan Todorov; Defu Zeng
Journal:  J Immunol       Date:  2012-05-30       Impact factor: 5.422

2.  IFN-γ receptor-deficient donor T cells mediate protection from graft-versus-host disease and preserve graft-versus-tumor responses after allogeneic bone marrow transplantation.

Authors:  Kai Sun; Hui-Hua Hsiao; Minghui Li; Erik Ames; Myriam Bouchlaka; Lisbeth A Welniak; Takeshi Hagino; Jared Jagdeo; Chien-Chun Pai; Mingyi Chen; Bruce R Blazar; Mehrdad Abedi; William J Murphy
Journal:  J Immunol       Date:  2012-07-09       Impact factor: 5.422

3.  Recipient myeloid-derived immunomodulatory cells induce PD-1 ligand-dependent donor CD4+Foxp3+ regulatory T cell proliferation and donor-recipient immune tolerance after murine nonmyeloablative bone marrow transplantation.

Authors:  Marie van der Merwe; Hossam A Abdelsamed; Aman Seth; Taren Ong; Peter Vogel; Asha B Pillai
Journal:  J Immunol       Date:  2013-11-04       Impact factor: 5.422

4.  The novel costimulatory programmed death ligand 1/B7.1 pathway is functional in inhibiting alloimmune responses in vivo.

Authors:  Jun Yang; Leonardo V Riella; Susanne Chock; Tao Liu; Xiaozhi Zhao; Xueli Yuan; Alison M Paterson; Toshihiko Watanabe; Vijay Vanguri; Hideo Yagita; Miyuki Azuma; Bruce R Blazar; Gordon J Freeman; Scott J Rodig; Arlene H Sharpe; Anil Chandraker; Mohamed H Sayegh
Journal:  J Immunol       Date:  2011-06-22       Impact factor: 5.422

Review 5.  Advances in targeting co-inhibitory and co-stimulatory pathways in transplantation settings: the Yin to the Yang of cancer immunotherapy.

Authors:  Leslie S Kean; Laurence A Turka; Bruce R Blazar
Journal:  Immunol Rev       Date:  2017-03       Impact factor: 12.988

6.  B7H1/CD80 interaction augments PD-1-dependent T cell apoptosis and ameliorates graft-versus-host disease.

Authors:  Ruishu Deng; Kaniel Cassady; Xiaofan Li; Sheng Yao; Mingfeng Zhang; Jeremy Racine; Jeffrey Lin; Lieping Chen; Defu Zeng
Journal:  J Immunol       Date:  2014-12-08       Impact factor: 5.422

Review 7.  Role of the PD-1 pathway in the immune response.

Authors:  L V Riella; A M Paterson; A H Sharpe; A Chandraker
Journal:  Am J Transplant       Date:  2012-08-17       Impact factor: 8.086

Review 8.  Advances in targeting cell surface signalling molecules for immune modulation.

Authors:  Sheng Yao; Yuwen Zhu; Lieping Chen
Journal:  Nat Rev Drug Discov       Date:  2013-02       Impact factor: 84.694

9.  Regulatory T-cell immunotherapy for allogeneic hematopoietic stem-cell transplantation.

Authors:  Matthew Horch; Vu H Nguyen
Journal:  Ther Adv Hematol       Date:  2012-02

Review 10.  The programmed death-1 immune-suppressive pathway: barrier to antitumor immunity.

Authors:  Suzanne Ostrand-Rosenberg; Lucas A Horn; Samuel T Haile
Journal:  J Immunol       Date:  2014-10-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.